戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  lipopolysaccharide (LPS) challenge and live Escherichia coli infection.
2 al role in protecting flies against systemic Escherichia coli infection.
3 gs was observed in MCP-1(-/-) mice following Escherichia coli infection.
4 e vagal system in mice delayed resolution of Escherichia coli infection.
5 lity to UTI was evaluated after experimental Escherichia coli infection.
6  role in the pathogenesis of extraintestinal Escherichia coli infection.
7  infection similar to levels observed during Escherichia coli infection.
8 lowing antibiotic treatment for a peritoneal Escherichia coli infection.
9 mation, and protects against enterotoxigenic Escherichia coli infection.
10 does not in itself make a fly susceptible to Escherichia coli infection.
11  ricin intoxication or Shiga toxin producing Escherichia coli infection.
12 nobactin showed efficacy in a mouse systemic Escherichia coli infection.
13 that regulates glycolysis following systemic Escherichia coli infection.
14 lity and bacterial burden following systemic Escherichia coli infection.
15  106 patients (76%), including 32 (30%) with Escherichia coli infection.
16 itrobacter rodentium was used to model human Escherichia coli infections.
17 tive actions increasing mice survival during Escherichia coli infections.
18 l for enteropathogenic and enterohemorrhagic Escherichia coli infections.
19 sociated with Enterococcus faecalis, but not Escherichia coli, infection.
20                                              Escherichia coli infections, a leading cause of septic s
21 investigate the role of IL-6 during virulent Escherichia coli infection and in lipopolysaccharide (LP
22 ed TNF-a, IL-6, and IL-10 following systemic Escherichia coli infection, and they exhibited increased
23                     Diseases associated with Escherichia coli infection are the subject of renewed in
24                              Extraintestinal Escherichia coli infections are associated with speciali
25                                              Escherichia coli infections are increasing worldwide in
26  were measured for their ability to clear an Escherichia coli infection at 1 and 4 weeks of age.
27  is down-regulated in response to Salmonella/Escherichia coli infection but is not affected by Staphy
28 ethoprim (TMP) is used to treat a variety of Escherichia coli infections, but its efficacy is limited
29     This infection process parallels that of Escherichia coli infection by the Ff family of filamento
30 contributes to the defense of the MG against Escherichia coli infection by using a mouse mastitis mod
31                        Shiga toxin-producing Escherichia coli infections can often lead to the develo
32 nfection, a mouse model for enteropathogenic Escherichia coli infection, Hvem-/- mice showed decrease
33 sk of recurrence of extraintestinal invasive Escherichia coli infections (IEIs) in the United States.
34 cter rodentium, a model for enteropathogenic Escherichia coli infection in humans, these macrophages
35  in large peritoneal macrophages (LPMs) upon Escherichia coli infection in mice.
36 bapenem-resistant Klebsiella pneumoniae, and Escherichia coli infection in mice.
37             Here, we confirm that peripheral Escherichia coli infection in neonates at postnatal day
38                                    Ascending Escherichia coli infection in pregnant mice induces PTB
39  innate immune response to LPS challenge and Escherichia coli infection in vivo.
40 ing an outbreak of sequence type 131 (ST131) Escherichia coli infections in a nursing home in The Net
41  inflammation from Staphylococcus aureus and Escherichia coli infections in vivo in a murine myositis
42                   Most human extraintestinal Escherichia coli infections, including those involving a
43 ndrome (HUS) caused by Shiga toxin-producing Escherichia coli infection is a leading cause of pediatr
44 ) caused by intestinal Shiga toxin-producing Escherichia coli infections is a worldwide health proble
45 S), which is caused by Shiga toxin-producing Escherichia coli infection, is the leading cause of acut
46                                              Escherichia coli infection isolates (n = 18) did not dif
47                      These molecules rescued Escherichia coli infection-mediated delay in tissue rege
48 ulmonary infection by using an intratracheal Escherichia coli infection model of pneumonia.
49 ke receptors (NLRs), we used an experimental Escherichia coli infection model using mice deficient in
50  relationship exists between enterotoxigenic Escherichia coli infections producing the exogenous GCC
51 cidal antibiotic gentamicin, given 3 h after Escherichia coli infection, protected Mkp-1(+/+) mice fr
52           We demonstrated that uropathogenic Escherichia coli infection stimulates the synthesis of I
53 es of studies were performed in rabbits with Escherichia coli infection: (Study A) Four groups of six
54 two- to threefold more susceptible to lethal Escherichia coli infection than cas-1(+/+) mice.
55                                           In Escherichia coli infection, the implications of fluoroqu
56 ator-metabololipidomics of murine peritoneal Escherichia coli infections with temporal identification